Finance entity
Every one of those 1 sits in a single category, earnings. Chiesi Global Rare Diseases is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6.4 for that window.
Last mentioned: Mar 18, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, earnings. Chiesi Global Rare Diseases is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6.4 for that window. Source depth averages 2 original sources per story, versus 2.4 across the same-window beat baseline. Protalix BioTherapeutics appears in 1 tracked Finance story from March 18, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 114 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Protalix BioTherapeutics. Shared-story counts are live from our verified record — not editorial picks.
General Mills and Protalix BioTherapeutics both reported disappointing quarterly results on Wednesday, missing analyst expectations on both revenue and earnings. Despite the immediate misses, both companies signaled long-term stability by reaffirming or providing full-year 2026 outlooks.
Protalix BioTherapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
